RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Xue Zhu to Antineoplastic Agents

This is a "connection" page, showing publications Xue Zhu has written about Antineoplastic Agents.
Connection Strength

0.314
  1. Frimpong E, Bulusu R, Okoro J, Inkoom A, Ndemazie N, Rogers S, Zhu X, Han B, Agyare E. Development of novel pyrimidine nucleoside analogs as potential anticancer agents: Synthesis, characterization, and In-vitro evaluation against pancreatic cancer. Eur J Pharm Sci. 2024 May 01; 196:106754.
    View in: PubMed
    Score: 0.120
  2. Ndemazie NB, Inkoom A, Ebesoh D, Bulusu R, Frimpong E, Trevino J, Han B, Zhu X, Agyare E. Synthesis, characterization, and anticancer evaluation of 1,3-bistetrahydrofuran-2yl-5-FU as a potential agent for pancreatic cancer. BMC Cancer. 2022 Dec 22; 22(1):1345.
    View in: PubMed
    Score: 0.110
  3. Asong G, Zhu XY, Bricker B, Andey T, Amissah F, Lamango N, Ablordeppey SY. New analogs of SYA013 as sigma-2 ligands with anticancer activity. Bioorg Med Chem. 2019 06 15; 27(12):2629-2636.
    View in: PubMed
    Score: 0.085
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support